Thermo Fisher Scientific Files Q1 Report, Reveals $1.075B Microbiology Business Divestiture, and Details Recent Acquisitions

summarizeSummary

Thermo Fisher Scientific reported strong Q1 2026 financial results, announced a new $1.075 billion divestiture, provided details on a $9.1 billion acquisition, and disclosed additional restructuring plans.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Reported Q1 2026 revenues of $11.005 billion, a 6% increase from $10.364 billion in Q1 2025. GAAP diluted EPS grew 11% to $4.43, and adjusted EPS increased 6% to $5.44, reflecting solid operational execution.

• Agreement to Divest Microbiology Business

  Entered into an agreement on April 27, 2026, to sell its microbiology business to Astorg for approximately $1.075 billion, consisting of cash and a $50 million seller note. The sale is expected to close in the second half of 2026.

• Completed $9.1 Billion Clario Holdings Acquisition

  Finalized the acquisition of Clario Holdings, Inc. on March 24, 2026, for a total purchase price of $9.099 billion. This expands the Laboratory Products and Biopharma Services segment with clinical research offerings.

• Significant Share Repurchases

  Repurchased $3.00 billion of common stock (4.9 million shares) during Q1 2026 under the $5.00 billion authorization from November 2025, with $2.00 billion remaining for future repurchases.

auto_awesomeAnalysis

This quarterly report provides comprehensive financial results for Q1 2026, confirming strong performance with increased revenues and EPS. While headline Q1 figures were previously announced, this filing introduces new material information, notably the agreement to divest the microbiology business for $1.075 billion, a strategic move to optimize the company's portfolio. It also details the completed $9.099 billion acquisition of Clario Holdings and outlines additional restructuring charges of $290 million aimed at streamlining operations. The continued significant share repurchases further underscore management's commitment to shareholder returns. Investors should view the divestiture as a positive step towards strategic focus and the overall financial health as robust, despite the near-term restructuring costs.